Messenger RNA, or mRNA, vaccine technology burst onto the scene early in the COVID pandemic, leaving many people playing catch-up on the science behind the advance. Within the first six months of ...
Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to ...
The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...
CAMBRIDGE, MA / ACCESS Newswire / February 10, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) has ...
Please provide your email address to receive an email when new articles are posted on . The FDA will now review an application for Moderna’s mRNA-1010 influenza vaccine. The agency initially rejected ...
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results